vTv Therapeutics Inc (NASDAQ:VTVT) major shareholder Ronald O. Perelman bought 1,879,699 shares of the business’s stock in a transaction that occurred on Tuesday, November 6th. The shares were acquired at an average price of $1.33 per share, for a total transaction of $2,499,999.67. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of vTv Therapeutics stock traded up $0.01 on Thursday, hitting $2.65. 7,431 shares of the company’s stock traded hands, compared to its average volume of 2,473,926. The firm has a market cap of $90.48 million, a price-to-earnings ratio of -1.59 and a beta of -3.71. vTv Therapeutics Inc has a one year low of $0.65 and a one year high of $8.40.
Separately, Zacks Investment Research lowered vTv Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 4th. Eight investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. vTv Therapeutics has an average rating of “Hold” and a consensus price target of $13.29.
COPYRIGHT VIOLATION NOTICE: “vTv Therapeutics Inc (VTVT) Major Shareholder Ronald O. Perelman Buys 1,879,699 Shares” was posted by Ticker Report and is owned by of Ticker Report. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3921580/vtv-therapeutics-inc-vtvt-major-shareholder-ronald-o-perelman-buys-1879699-shares.html.
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.
Read More: Stop Order Uses For Individual Investors
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.